We recently published a list of 12 Safe Stocks to Buy for the Long Term in 2025. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other safe stocks to ...

In his opening remarks, Idaho Senator Mike Crapo, the Finance committee's chairman, praised Kennedy's “commitment to ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

At 47, tech millionaire Bryan Johnson, ‘The man who wants to live forever,’ has abandoned a controversial longevity drug amidst fears that it might be accelerating his aging, contrary to its ...

Bryan Johnson, a 47-year-old IT entrepreneur and anti-aging advocate, announced a few days ago that he had stopped taking rapamycin that was part of his personal experiment in the quest for longevity.

Johnson & Johnson announced it has initiated the submission of an original New Drug Application with the U.S. FDA for TAR-200 for the treatment of patients with Bacillus Calmette-Guerin ...

Known for spending millions of dollars on his quest to reverse aging, Johnson recently revealed that he has stopped taking a once-promising de-aging drug, rapamycin, over concerns that it may have ...

The FDA's rule proposal would ... Related House Speaker Johnson orders flags to be raised, despite mourning period for Jimmy Carter Trump proposes 'External Revenue Service' to tax foreign ...

Distributor death:ECSO: Alleged drug distributor killed his ... They found a deceased man, later identified as Johnson, dead of a gunshot wound in the driver's seat of a brown Chevrolet Malibu.

Intra-Cellular Therapies sells one drug treating schizophrenia and bipolar ... are surging 35% in premarket trading Monday after Johnson & Johnson (JNJ) said it will acquire the biopharmaceutical ...